Daunomycin-polypeptide conjugates with antitumor activity.
Biochim Biophys Acta. 2010.
PMID: 20659420
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1976 | 1 |
| 1982 | 1 |
| 1984 | 1 |
| 1986 | 1 |
| 1990 | 1 |
| 1991 | 1 |
| 1992 | 1 |
| 1993 | 2 |
| 1994 | 1 |
| 1995 | 1 |
| 1997 | 2 |
| 1998 | 1 |
| 1999 | 3 |
| 2000 | 10 |
| 2001 | 5 |
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 2 |
| 2009 | 4 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 7 |
| 2013 | 11 |
| 2014 | 16 |
| 2015 | 20 |
| 2016 | 27 |
| 2017 | 18 |
| 2018 | 14 |
| 2019 | 18 |
| 2020 | 11 |
| 2021 | 12 |
| 2022 | 8 |
| 2023 | 7 |
| 2024 | 9 |
| 2025 | 6 |
Search Results
220 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Daunomycin-polypeptide conjugates with antitumor activity.
Biochim Biophys Acta. 2010 Dec;1798(12):2209-16. doi: 10.1016/j.bbamem.2010.07.023. Epub 2010 Jul 24.
Biochim Biophys Acta. 2010.
PMID: 20659420
Free article.
We have developed a group of water-soluble drug conjugates in which daunomycin (Dau) is coupled to cationic, amphoteric or anionic branched polypeptides and a new conjugate containing a cationic polypeptide carrier modified with a cell penetrati …
We have developed a group of water-soluble drug conjugates in which daunomycin (Dau) is coupled to cationic, amphoteric or ani …
Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
Beilstein J Org Chem. 2018 Apr 25;14:911-918. doi: 10.3762/bjoc.14.78. eCollection 2018.
Beilstein J Org Chem. 2018.
PMID: 29765472
Free PMC article.
Cyclic NGR peptides as homing devices are good candidates for the development of drug conjugates for targeted tumor therapy. In our previous study we reported that the Dau=Aoa-GFLGK(c[KNGRE]-GG-)-NH(2) conjugate has a significant antitumor activity …
Cyclic NGR peptides as homing devices are good candidates for the development of drug conjugates for targeted tumor therapy. I …
New Transferrin Receptor-Targeted Peptide-Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity.
Molecules. 2024 Apr 12;29(8):1758. doi: 10.3390/molecules29081758.
Molecules. 2024.
PMID: 38675578
Free PMC article.
Poor selectivity to tumor cells is a major drawback in the clinical application of the antitumor drug doxorubicin (DOX). Peptide-drug conjugates (PDCs) constructed by modifying antitumor drugs with peptide ligands that have high affinity to certain overexpres …
Poor selectivity to tumor cells is a major drawback in the clinical application of the antitumor drug doxorubicin (DOX). Peptide-drug …
Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
Beilstein J Org Chem. 2018 Sep 26;14:2495-2509. doi: 10.3762/bjoc.14.226. eCollection 2018.
Beilstein J Org Chem. 2018.
PMID: 30344773
Free PMC article.
In this study our aim was (i) to analyze the effects of GnRH-drug conjugates on melanoma cell proliferation, adhesion and migration, (ii) to study the mechanisms of tumor cell responses, and (iii) to compare the activities of conjugates with the free drug. .. …
In this study our aim was (i) to analyze the effects of GnRH-drug conjugates on melanoma cell proliferation, adhesion and migration, …
NGR-peptide-drug conjugates with dual targeting properties.
PLoS One. 2017 Jun 2;12(6):e0178632. doi: 10.1371/journal.pone.0178632. eCollection 2017.
PLoS One. 2017.
PMID: 28575020
Free PMC article.
We synthesized small cyclic NGR peptide-daunomycin conjugates using NGR peptides of varying stability (c[KNGRE]-NH2, Ac-c[CNGRC]-NH2 and the thioether bond containing c[CH2-CO-NGRC]-NH2, c[CH2-CO-KNGRC]-NH2). ...Our results confirm the influence of structure …
We synthesized small cyclic NGR peptide-daunomycin conjugates using NGR peptides of varying stability (c[KNGRE]-NH2, Ac …
Antitumor activity of alpha fetoprotein and epidermal growth factor conjugates in vitro and in vivo.
Tumour Biol. 2000 Nov-Dec;21(6):367-74. doi: 10.1159/000030142.
Tumour Biol. 2000.
PMID: 11006577
Free article.
The antitumor effects of the conjugates were studied in vivo in mice with subcutaneous tumors of B16 and P388 cells. ...Our results suggest that the therapeutic activity of Cm can be significantly enhanced by conjugation to AFP or EGF....
The antitumor effects of the conjugates were studied in vivo in mice with subcutaneous tumors of B16 and P388 cells. ...Our re …
Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity.
Int Immunopharmacol. 2014 Jan;18(1):20-6. doi: 10.1016/j.intimp.2013.11.002. Epub 2013 Nov 12.
Int Immunopharmacol. 2014.
PMID: 24239629
It was purified using a His-Tag Ni-Agarose column and identified by western blot. The activity of Trx-ScFv-SA3 was verified by enzyme-linked immunosorbent assay (ELISA) and immunocytochemistry to confirm that it specifically binds to the hepatocellular carcinoma cell line …
It was purified using a His-Tag Ni-Agarose column and identified by western blot. The activity of Trx-ScFv-SA3 was verified by enzyme …
Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.
Int J Cancer. 2011 Oct 15;129(8):2002-12. doi: 10.1002/ijc.25859. Epub 2011 Apr 13.
Int J Cancer. 2011.
PMID: 21165950
Importantly, we show that the conjugate has significantly lower immunosuppressive activity than free doxorubicin when using dosage with comparable antitumor activity, thus eliminating the majority of tumor cells while leaving the immune system mostly u …
Importantly, we show that the conjugate has significantly lower immunosuppressive activity than free doxorubicin when using do …
Furan-Conjugated Tripeptides as Potent Antitumor Drugs.
Biomolecules. 2020 Dec 16;10(12):1684. doi: 10.3390/biom10121684.
Biomolecules. 2020.
PMID: 33339257
Free PMC article.
In the current study, we have identified a new peptide conjugate (Fur(4)-2-Nal(3)-Ala(2)-Phe(1)-CONH(2)) (conjugate 4), from screening of a small library of tripeptide-conjugates of furan, as highly potent anticancer compound against human cervical cancer cel …
In the current study, we have identified a new peptide conjugate (Fur(4)-2-Nal(3)-Ala(2)-Phe(1)-CONH(2)) (conjugate 4), from s …
Galactosylated alpha,beta-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.
Anticancer Drugs. 2011 Feb;22(2):136-47. doi: 10.1097/CAD.0b013e3283406e85.
Anticancer Drugs. 2011.
PMID: 20966743
Gal-PHEA-DOX exhibited comparable antitumor activity with PHEA-DOX in the S180-bearing mice, but more effective than PHEA-DOX or DOX in the Heps-bearing mice with negligible detrimental effect in the liver remnant. ...These results suggest that the Gal-PHEA-DOX c …
Gal-PHEA-DOX exhibited comparable antitumor activity with PHEA-DOX in the S180-bearing mice, but more effective than PHEA-DOX …
Cite